Award
NIH Reporter #7R01CA292084-02
Pharmacodynamically directed targeted therapy for leukemia
Recipient
University of Pittsburgh at Pittsburgh
Award Amount
$694,315.00
Ceiling
$694,315.00
Awarded
September 08, 2026
Identifier
7R01CA292084-02
NIH awarded $694,315 to University of Pittsburgh for developing a targeted therapy for AML using DHODH inhibitor HOSU-53, focusing on TP53 mutated cases, including clinical trials and advanced monitoring techniques.
Description
This project aims to develop a targeted therapy using a potent DHODH inhibitor (HOSU-53) for Acute Myeloid Leukemia (AML), focusing on TP53 mutated AML. It includes preclinical development, IND enabling studies, and the first-in-human clinical trial with pharmacokinetic, pharmacodynamic, and single-cell DNA sequencing monitoring.